No Cover Image

Journal article 411 views 36 downloads

Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups

Chinyereugo M. Umemneku-Chikere, Olubukola Ayodele, Marta Soares, Sam Khan, Keith Abrams, Rhiannon Owen Orcid Logo, Sylwia Bujkiewicz

Frontiers in Oncology, Volume: 12

Swansea University Author: Rhiannon Owen Orcid Logo

  • 60626_VoR.pdf

    PDF | Version of Record

    © 2022 Umemneku-Chikere, Ayodele, Soares, Khan, Abrams, Owen and Bujkiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

    Download (2.65MB)

Check full text

DOI (Published version): 10.3389/fonc.2022.943154

Abstract

Breast cancer is the fifth leading cause of cancer related deaths worldwide. Randomised controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2) positive advanced breast cancer (ABC) have provided evidence base for regulatory and reimbursement agencies to appraise the use...

Full description

Published in: Frontiers in Oncology
ISSN: 2234-943X
Published: Frontiers Media SA 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60626
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-08-05T12:42:26Z
last_indexed 2023-01-13T19:20:53Z
id cronfa60626
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-08-22T11:51:32.6435240</datestamp><bib-version>v2</bib-version><id>60626</id><entry>2022-07-25</entry><title>Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups</title><swanseaauthors><author><sid>0d30aa00eef6528f763a1e1589f703ec</sid><ORCID>0000-0001-5977-376X</ORCID><firstname>Rhiannon</firstname><surname>Owen</surname><name>Rhiannon Owen</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-07-25</date><deptcode>HDAT</deptcode><abstract>Breast cancer is the fifth leading cause of cancer related deaths worldwide. Randomised controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2) positive advanced breast cancer (ABC) have provided evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbour additional biomarkers e.g. a positive hormone receptor status which may be more amenable to therapy, and improve overall survival. This review seeks to explore the reporting of evidence for treatment effects by hormone receptor status using the RCTs evidence of targeted therapies for HER2 positive ABC patients. PRISMA guidelines were followed to identify published RCTs. Extracted data were synthesised using network meta-analysis and relative effects of HER2 positive targeted therapies were obtained. We identified a gap in the reporting of the effectiveness of therapies by hormone receptor subgroups as only 15 out of 42 identified RCTs reported hormone receptor status analyses; majority of which reported progression free survival (PFS), but not overall survival (OS) or overall response rate (ORR). In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups.</abstract><type>Journal Article</type><journal>Frontiers in Oncology</journal><volume>12</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Frontiers Media SA</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2234-943X</issnElectronic><keywords>Advanced breast cancer, hormone receptor, HER2 positive, metastatic breast cancer,targeted therapies, network meta-analysis, subgroup analysis</keywords><publishedDay>18</publishedDay><publishedMonth>8</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-08-18</publishedDate><doi>10.3389/fonc.2022.943154</doi><url/><notes>Data availability: All data used in this manuscript are reported in the supplementary file 1 and can all be access online.</notes><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This work was supported by Medical Research Council, Methodology Research Panel grant [MR/T025166/1]</funders><projectreference/><lastEdited>2022-08-22T11:51:32.6435240</lastEdited><Created>2022-07-25T12:13:17.4308766</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Chinyereugo M.</firstname><surname>Umemneku-Chikere</surname><order>1</order></author><author><firstname>Olubukola</firstname><surname>Ayodele</surname><order>2</order></author><author><firstname>Marta</firstname><surname>Soares</surname><order>3</order></author><author><firstname>Sam</firstname><surname>Khan</surname><order>4</order></author><author><firstname>Keith</firstname><surname>Abrams</surname><order>5</order></author><author><firstname>Rhiannon</firstname><surname>Owen</surname><orcid>0000-0001-5977-376X</orcid><order>6</order></author><author><firstname>Sylwia</firstname><surname>Bujkiewicz</surname><order>7</order></author></authors><documents><document><filename>60626__24986__74b3f3ee7e154803975064759257c32f.pdf</filename><originalFilename>60626_VoR.pdf</originalFilename><uploaded>2022-08-22T11:49:30.9795650</uploaded><type>Output</type><contentLength>2780874</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2022 Umemneku-Chikere, Ayodele, Soares, Khan, Abrams, Owen and Bujkiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-08-22T11:51:32.6435240 v2 60626 2022-07-25 Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups 0d30aa00eef6528f763a1e1589f703ec 0000-0001-5977-376X Rhiannon Owen Rhiannon Owen true false 2022-07-25 HDAT Breast cancer is the fifth leading cause of cancer related deaths worldwide. Randomised controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2) positive advanced breast cancer (ABC) have provided evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbour additional biomarkers e.g. a positive hormone receptor status which may be more amenable to therapy, and improve overall survival. This review seeks to explore the reporting of evidence for treatment effects by hormone receptor status using the RCTs evidence of targeted therapies for HER2 positive ABC patients. PRISMA guidelines were followed to identify published RCTs. Extracted data were synthesised using network meta-analysis and relative effects of HER2 positive targeted therapies were obtained. We identified a gap in the reporting of the effectiveness of therapies by hormone receptor subgroups as only 15 out of 42 identified RCTs reported hormone receptor status analyses; majority of which reported progression free survival (PFS), but not overall survival (OS) or overall response rate (ORR). In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups. Journal Article Frontiers in Oncology 12 Frontiers Media SA 2234-943X Advanced breast cancer, hormone receptor, HER2 positive, metastatic breast cancer,targeted therapies, network meta-analysis, subgroup analysis 18 8 2022 2022-08-18 10.3389/fonc.2022.943154 Data availability: All data used in this manuscript are reported in the supplementary file 1 and can all be access online. COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University This work was supported by Medical Research Council, Methodology Research Panel grant [MR/T025166/1] 2022-08-22T11:51:32.6435240 2022-07-25T12:13:17.4308766 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Chinyereugo M. Umemneku-Chikere 1 Olubukola Ayodele 2 Marta Soares 3 Sam Khan 4 Keith Abrams 5 Rhiannon Owen 0000-0001-5977-376X 6 Sylwia Bujkiewicz 7 60626__24986__74b3f3ee7e154803975064759257c32f.pdf 60626_VoR.pdf 2022-08-22T11:49:30.9795650 Output 2780874 application/pdf Version of Record true © 2022 Umemneku-Chikere, Ayodele, Soares, Khan, Abrams, Owen and Bujkiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). true eng http://creativecommons.org/licenses/by/4.0/
title Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
spellingShingle Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
Rhiannon Owen
title_short Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
title_full Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
title_fullStr Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
title_full_unstemmed Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
title_sort Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
author_id_str_mv 0d30aa00eef6528f763a1e1589f703ec
author_id_fullname_str_mv 0d30aa00eef6528f763a1e1589f703ec_***_Rhiannon Owen
author Rhiannon Owen
author2 Chinyereugo M. Umemneku-Chikere
Olubukola Ayodele
Marta Soares
Sam Khan
Keith Abrams
Rhiannon Owen
Sylwia Bujkiewicz
format Journal article
container_title Frontiers in Oncology
container_volume 12
publishDate 2022
institution Swansea University
issn 2234-943X
doi_str_mv 10.3389/fonc.2022.943154
publisher Frontiers Media SA
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Breast cancer is the fifth leading cause of cancer related deaths worldwide. Randomised controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2) positive advanced breast cancer (ABC) have provided evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbour additional biomarkers e.g. a positive hormone receptor status which may be more amenable to therapy, and improve overall survival. This review seeks to explore the reporting of evidence for treatment effects by hormone receptor status using the RCTs evidence of targeted therapies for HER2 positive ABC patients. PRISMA guidelines were followed to identify published RCTs. Extracted data were synthesised using network meta-analysis and relative effects of HER2 positive targeted therapies were obtained. We identified a gap in the reporting of the effectiveness of therapies by hormone receptor subgroups as only 15 out of 42 identified RCTs reported hormone receptor status analyses; majority of which reported progression free survival (PFS), but not overall survival (OS) or overall response rate (ORR). In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups.
published_date 2022-08-18T04:18:53Z
_version_ 1763754255389294592
score 11.013148

Similar Items